Characteristics of citalopram plus Wuling capsule in the treatment of general anxiety disorder
Qiang Li,Wei Wang,Ce Chen,Ya-mei Li
DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.39.002
2006-01-01
Abstract:Aim: To observe the clinical characteristics of Wuling capsule and citalopram in the treatment of generalized anxiety disorder (GAD). Methods: Seventy-four out-patients with GAD from October 2005 to May 2006 were selected from Department of Psychiatry, First Affiliated Hospital of Medical College, Xi'an Jiao Tong University. All patients were divided into two groups according to their numbers of visiting and diagnosis, patients with odd numbers were assigned into study group (n=38) and those with even numbers were assigned into control group (n=36). 1 Patients in the control group were treated by orally taking 20 mg of citalopram once a day in the morning. Those in the study group were treated orally with 20 mg of citalopram combined with 0.99 g of Wuling capsule three times a day. Patients with severe insomnia were given 0.5-1.0 mg of Lorazepam additionally. The treatment course for patients in the two groups was 6 weeks. 2 Anxiety and depression levels of patients were evaluated with Hamilton Anxiety Rating Scale (HAMA) and Hamilton Depression Rating Scale (HAMD) respectively before treatment and 1, 2, 4, 6 weeks after the treatment. The decreased percent of HAMA was taken as the evaluation indicator: invalid as ≤30%, improved as between 31% and 49%, remarkably improved as between 50% and 79%, clinically healed as ≥ 80%. 3 The side effects were measured with TESS. Results: Eight patients in the study group and six patients in the control group withdrew from the study respectively, because they were unable to receive the reassessment and psychological test. Thirty patients in the study group and 30 patients in control group were involved in the analysis of results. 1 The total score of HAMA: There were significant differences in the study group before treatment in comparison with that at the end of the 1st, 2nd, 4th, 6th weeks after the treatment (13.8±4.1,11.7±3.8,9.8±3.5, 8.3±2.9,21.5±5.8,P < 0.01).There were significant differences in the control group at the end of the 2nd, 4th and 6th weeks in comparison with those before treatment (13.8±3.6, 10.3±3.4, 8.1±3.2,20.9±5.3, P < 0.01) 2 The overall score of HAMD: There were significant differences from the end of the 2nd week between the study group and control group (10.7±3.1, 16.8±5.9; 10.1±3.0,15.9±5.2,P < 0.05), and there were significant differences at the end of the 4th and 6th weeks between the study group and control group (study group: 9.0±2.6,7.3±1.9,16.8±5.9; control group: 8.9±2.4, 7.5±2.1,15.9±5.2,P < 0.01). 3 The utilization of Lorazepam in the control group was significantly higher than that in the study group (78.0%, 36.5%,P < 0.01), and the average dose of Lorazepam in the control group was obviously higher than that in the study group [(40.00±14.25) mg/d, (33.00±12.20) mg/d,P < 0.05]. 4 The efficiency at the end of the first week was significantly higher in the study group than that in the control group (53.5%,3.9%,P < 0.01), and it was still remarkably higher at the end of the second week in the study group than that in the control group (89.0%,78.0%,P < 0.05). 5 At the end of the 4th week, the score of TESS in the control group was significantly higher than that in the study group (4.35±1.23,3.26±1.12,P < 0.01). Conclusion: Citalopram integrated with Wuling capsule has a quicker effect than that by just using of citalopram. Citalopram is small in dose with less side effects.